Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
In Unusual Move, Huawei Offers ‘No Backdoor’ Deal to India Amid Security Concerns: Report
China Races Ahead of U.S. in Deployment of Electric-Vehicle Charging Stations
Do ‘Double 11’ Vendors Have to Pick Sides This Year? Alibaba Says It’s ‘Normal Market Behavior’
LATEST
Huawei Posts Strong Revenue Growth Despite U.S. Export Ban
Ant Financial Seeks Loan of as Much as $3.5 Billion at Lower Rate
China Freezes Some Social Media, Mobile Payment Accounts in Myanmar Cross-Border Fraud Crackdown
Popular Translation App Youdao Downsizes New York IPO
Popular Alibaba-Backed Social E-Commerce App Returns After Months-Long Absence
Cheap-Phone Maker Realme Eyes Upscale Turn With Pricey New Handset
State Council Order Formalizes Further Opening of Chinese Financial Sector
IMF Predicts Slower Economic Growth for 2019
China Nails Down Timeline for Long-Awaited Mobile Number Portability Program: Report
China Races Ahead of U.S. in Deployment of Electric-Vehicle Charging Stations
Bird Rides Scooter Maker Sees Profit Surge on Overseas Orders
Germany Leaves 5G Door Open to Huawei, Reuters Reports
Cash-Strapped Bike-Sharing App Ofo Says It “Hasn’t Given Up”
Do ‘Double 11’ Vendors Have to Pick Sides This Year? Alibaba Says It’s ‘Normal Market Behavior’
China’s Cloud Computing Market Still Far Behind U.S.: Think Tank
Weather-Forecast App Operator Denied Shenzhen Listing
China’s Wealthy Eastern Regions Report Shrinking Industrial Profits
In Unusual Move, Huawei Offers ‘No Backdoor’ Deal to India Amid Security Concerns: Report
Apple Under Fire for Handing Over Some Web Browsing Data to Tencent
China’s Tencent Resumes Streaming NBA Games
China Approves Older Novartis MS Drug

By Matthew Walsh / Jul 20, 2019 05:37 AM / Business & Tech

Photo: VCG

Photo: VCG

Novartis International AG won approval in China to sell its multiple sclerosis (MS) drug Gilenya, Reuters reports, deepening the Swiss pharmaceutical giant's business ties to the huge Chinese health care market and promising to shake up the treatment of what has traditionally been a poorly managed disease there.

MS is the most common autoimmune disease affecting the central nervous system. Around 30,000 people in China live with the condition, according to state news agency Xinhua. That compares with nearly 1 million people in the U.S. suffering the disease, according to a study by the National MS Society.

However, low awareness of MS in China means that the actual number of people with the disease may be significantly higher. In May, Chinese doctors urged both health-care professionals and the general public to learn more about the disease, adding that 95% of people knew nothing about MS before they were diagnosed.

MS occurs when the body’s immune system attacks the fatty sheaths around the nerves, disrupting their ability to send messages to one another. As MS progresses, it causes muscle and cognitive problems and can lead to lasting disabilities.

Although there is no one-size-fits-all cure, a number of treatments can significantly slow the progression of MS. China has long been playing catch-up with Western countries in rolling out such treatments, however, and comparatively few are yet available there.

One such drug, teriflunomide — sold under the trademark Aubagio — was approved by the U.S. Food and Drug Administration in 2012 but gained approval in China only last year.

Gilenya sales earned Novartis $825 million during the second quarter, making it the company’s second-largest source of revenue, Reuters said, adding that the drug has been available in the United States for almost a decade but is now being challenged by generic rivals, spurring Novartis’s push into other markets.

Related: In Depth: Why China’s Drug Review Revamp Is Stalling

Contact reporter Matthew Walsh (matthewwalsh@caixin.com)

Share this article
Open WeChat and scan the QR code